Cabaletta Bio, Inc.
NASDAQ:CABABiotechnology
+$0.04 today
- Market cap
- $227.58M
- Beta
- 3.23
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.57
Volume 4.13M
Average 3.33M
CABA Net Income
Bottom-line profit after all expenses, interest, and taxes.
Cabaletta Bio, Inc.NASDAQ: CABA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$43.52M, compared with -$35.94M a year earlier. Trailing-twelve-month net income was -$175.43M.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$133.66M (+20.4%) for the fiscal year ending Dec 2026, a step up from the -44.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$43.52M-3.8% QoQ
- Last fiscal yearDec 2025
- -$167.86M-44.9% YoY
- LTMMar 2026
- -$175.43M-38.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -21.1% | +7.4% | +28.5 pp |
| 1 year | -44.9% | +20.4% | +65.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (167.86M) USD
- Year-over-year change
- -44.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (167.86M) | -44.9% |
| FY2024 | 2024-12-31 | (115.86M) | -71.2% |
| FY2023 | 2023-12-31 | (67.68M) | -27.7% |
| FY2022 | 2022-12-31 | (52.98M) | -14.4% |
| FY2021 | 2021-12-31 | (46.29M) | — |
Net Income vs competitors
How CABA compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -38.4% is the 8th highest of 11, against a peer median of -14.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -€45.62M EUR | -51.2% | — | 339.4% | |
| FY2025 | -A$61.43M AUD | -43.8% | — | 1218.0% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$87.5M USD | +19.9% | — | — |
| LTM Mar 2026 | -$97.59M USD | -25.7% | — | 4840.8% | |
| LTM Mar 2026 | -$108.95M USD | +56.6% | — | 281.6% | |
| LTM Mar 2026 | -$114.59M USD | -108.1% | — | — | |
| LTM Mar 2026 | -$156.4M USD | -7.6% | — | — | |
| LTM Mar 2026 | -$169.52M USD | -21.5% | — | — | |
| LTM Mar 2026 | -$173.76M USD | +31.1% | — | — | |
| LTM Mar 2026 | -$175.43M USD | -38.4% | — | — | |
| LTM Mar 2026 | -$246.41M USD | +26.3% | — | 794858.1% | |
| Peer median (excluding CABA) | — | -14.5% | — | 1218.0% | |
Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.49M | 39.3M | 55.42M | 97.2M | 142.67M |
| Selling, General & Admin | 13.82M | 14.84M | 19.24M | 27.94M | 29.57M |
| Operating Expenses | 46.31M | 54.14M | 74.66M | 125.14M | 172.24M |
| Depreciation & Amortization | 733K | 1.18M | 1.43M | 1.71M | 1.65M |
| EBITDA | (45.56M) | (51.8M) | (66.25M) | (113.41M) | (164.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (46.31M) | (54.14M) | (74.66M) | (125.14M) | (172.24M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 24K | 1.16M | 6.99M | 10.03M | 6.03M |
| Interest Expense | 0 | 0 | 0 | 748K | 2M |
| Other Income / Expenses | 24K | 1.16M | 6.99M | 9.28M | 4.39M |
| Income Before Tax | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.80) | (1.81) | (1.65) | (2.34) | (1.64) |
| EPS (Diluted) | (1.80) | (1.81) | (1.65) | (2.34) | (1.64) |
| Weighted Avg Shares | 25.74M | 29.34M | 40.95M | 49.52M | 102.26M |
| Weighted Avg Shares (Diluted) | 25.74M | 29.34M | 40.95M | 49.47M | 102.26M |
Cabaletta Bio, Inc.
NASDAQ:CABA
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.